Why Regulatory Affairs Is a Career with Job Security
In 2024–2026, the pharmaceutical industry faced a record increase in regulatory requirements. According to the FDA, the average approval time for a new drug (New Drug Application, NDA) in 2024 was about 10 months for priority applications and 12–14 months for standard ones. In 2025, the EMA reported an average review period for a Marketing Authorisation Application (MAA) of 13–15 months. At the same time, the rejection rate at the review stage reaches 20–30% — and most rejections are related to deficiencies in the dossier, not to the ineffectiveness of the drug.
That is precisely why Regulatory Affairs (RA) specialists are becoming key figures in bringing a product to market. They are responsible for preparing documentation, interacting with regulators, and complying with GxP requirements. Demand for such experts is growing: according to LinkedIn, the number of RA vacancies over the past two years increased by 18% in Europe and by 22% in the United States.
But it is almost impossible to enter the profession without practical knowledge of the eCTD format, GMP/GCP requirements, and an understanding of the differences between the FDA and EMA. The course "FDA/EMA — Regulatory Affairs for Pharmaceuticals" on the asibiont.com platform was created to close this gap.
What the Course Offers: From IND to MAA
The course program is built around the real tasks that an RA specialist faces every day. You will learn to:
- Prepare and submit dossiers in eCTD format (Electronic Common Technical Document) — a mandatory standard for the FDA and EMA. You will study the module structure, PDF file requirements, and validation specifics.
- Understand the differences between regulatory pathways: IND (Investigational New Drug), NDA, ANDA, 510(k), PMA for the United States and MAA, variations, renewals for the EU.
- Understand GMP/GLP/GCP requirements and pass inspections: from site preparation to responses to Form 483 and Warning Letters.
- Build post-marketing surveillance: pharmacovigilance, periodic reports (PSUR), change management.
- Use ready-made document templates for IND, NDA, MAA — this saves months of work.
The course does not just provide theory — it simulates real work situations. For example, how to draft a submission plan if you only have preclinical study data, or how to respond to a regulator's request within tight deadlines.
How Learning Works on asibiont.com
The asibiont.com platform uses AI generation of personalized lessons. After registering, you indicate your level (beginner, experienced specialist, manager) and goals (change profession, improve qualifications, bring a specific product to market). The neural network creates an individual program: for a beginner — more fundamentals, for an experienced specialist — advanced cases on eCTD and inspections.
All lessons are text-based and available 24/7. You can ask the AI assistant questions and receive explanations of complex topics — for example, how to interpret the FDA guidance on clinical trials or how EMA requirements for GCP inspections differ. The AI explains in simple language, provides examples, and gives practical assignments: draft a dossier fragment, fill out a form, analyze a rejection case.
This format is especially effective for busy professionals: there is no need to adjust to a webinar schedule, and the material adapts to your pace.
Who the Course Is For
- Beginning RA specialists — to gain systematic knowledge and avoid drowning in hundreds of pages of regulatory guidance.
- Employees of CROs and pharmaceutical companies — to move from clinical research or QA into Regulatory Affairs.
- Startup owners — to understand how to bring a drug to the U.S. or EU market without mistakes that cost millions.
- Medical writers — to master eCTD standards and learn to prepare documents for submission.
A Case from Practice: How an eCTD Error Cost 6 Months
A European biopharmaceutical company submitted an MAA to the EMA in 2024. The dossier was prepared in eCTD format, but with violations: Module 3 (Quality) lacked validated PDF files, and Module 5 (Clinical Study Reports) did not comply with the requirements for the structure of datasets. As a result, the EMA returned the application to the validation stage, which delayed the review by 6 months. The company lost not only time but also money — each month of delay in market entry cost an average of €1–2 million in lost revenue.
This case shows how important the details are. The asibiont.com course specifically teaches you how to avoid such mistakes: you will review real validation examples, learn to check the dossier before submission, and understand how to respond to regulator requests.
Why AI Learning Is Effective
Traditional Regulatory Affairs courses are often overloaded with theory and do not account for individual gaps. The AI on asibiont.com analyzes your answers and adjusts the program: if you are confused about GCP inspections, the system will offer additional materials and examples. If you already know the basics of eCTD, you will move on to complex scenarios.
In addition, the AI assistant is available at any time: you can ask a question at night or on weekends and receive a detailed answer. This is especially valuable when you are working on a real project and need quick consultation.
Start a Career in Regulatory Affairs
Regulatory Affairs is not just bureaucracy, but a strategic function on which a drug's success on the market depends. If you want to master an in-demand profession, learn to prepare dossiers for the FDA and EMA, and bring a product to the two largest markets simultaneously, start learning on asibiont.com. The course FDA/EMA — Regulatory Affairs for Pharmaceuticals will give you practical skills and confidence in the future.
Comments